home / stock / evok / evok news


EVOK News and Press, Evoke Pharma Inc. From 08/17/21

Stock Information

Company Name: Evoke Pharma Inc.
Stock Symbol: EVOK
Market: NASDAQ
Website: evokepharma.com

Menu

EVOK EVOK Quote EVOK Short EVOK News EVOK Articles EVOK Message Board
Get EVOK Alerts

News, Short Squeeze, Breakout and More Instantly...

EVOK - Virpax Pharmaceuticals, Sesen Bio leads healthcare gainers; Qualigen Therapeutics, Sema4 among major losers

Gainers: Virpax Pharmaceuticals (NASDAQ:VRPX) +96%, Sesen Bio (NASDAQ:SESN) +28%, Terns Pharmaceuticals (NASDAQ:TERN) +16%, 23andMe (NASDAQ:ME) +16%, NanoVibronix (NASDAQ:NAOV) +9%. Losers: Qualigen Therapeutics (NASDAQ:QLGN) -16%, Sema4 ...

EVOK - HVBT, PSTI and DPW among pre market gainers

Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy endpoint in late-stag...

EVOK - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It’s been a while but we’re back at it with a look at the biggest pre-market stock movers for Monday. Source: f11photo/Shutterstock.com But before that, take a quick second to c...

EVOK - Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2021 Results - Earnings Call Transcript

Evoke Pharma, Inc. (EVOK) Q2 2021 Results Conference Call August 12, 2021 04:30 PM ET Company Participants Christine Petraglia - The Ruth Group David Gonyer - Chief Executive Officer Matt D'Onofrio - Chief Business Officer Chris Quesenberry - Chief Commercial Officer, Gimoti Conference Call P...

EVOK - Evoke Pharma Reports Second Quarter 2021 Financial Results

Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), ...

EVOK - Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021

SOLANA BEACH, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its second quarter 2021 financial re...

EVOK - Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) August Gastroparesis Awareness Month

SOLANA BEACH, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma ® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA ™ , a leading provider of global commercialization services to the life scienc...

EVOK - Evoke Pharma Launches Gimoti® Patient and Physician Experience Program

SOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the start of additional marketing initiatives focusing on the launch of a patient and physi...

EVOK - Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD's Industry Council

SOLANA BEACH, Calif., CHICAGO, and MOUNT PLEASANT, S.C., June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, EVERSANA™, a leading provider of global commercial services to th...

EVOK - Evoke Pharma announces positive findings from second GIMOTI market research study

Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.The study aimed to gather further market insights on perception of GIMOTI in the GI community. In May 2021, Evoke’s commercialization partner, EVER...

Previous 10 Next 10